These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37972960)

  • 1. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 4. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
    Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
    Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
    Tamhankar MA; Pradeep T; Chen Y; Briceño CA
    J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
    Mudalegundi S; Huang P; Henderson AD; Carey AR
    J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
    Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
    Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teprotumumab for the treatment of chronic thyroid eye disease.
    Ugradar S; Kang J; Kossler AL; Zimmerman E; Braun J; Harrison AR; Bose S; Cockerham K; Douglas RS
    Eye (Lond); 2022 Aug; 36(8):1553-1559. PubMed ID: 34244669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Dallalzadeh LO; Liu CY
    Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
    Hwang CJ; Rebollo NP; Mechels KB; Perry JD
    Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease.
    Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO
    Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
    Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
    Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.